Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Daiichi Sankyo
Daiichi Sankyo
Activities:
Packaging
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials
Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer
Denis will be responsible for optimising global operations for the company
SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Therapeutic: datopotamab deruxtecan for breast cancer
Of all the various forms of breast cancer, triple negative is the most aggressive subtype
Research & Development
AstraZeneca and Daiichi Sankyo reveal phase 3 lung cancer study
Results for the TROP2-directed antibody drug conjugate demonstrated statistically significant improvement in progression-free survival vs. standard chemotherapy
Drug Delivery
ProLynx collaborates with Daiichi Sankyo on drug delivery
The collaboration will evaluate the utility of the releasable linker technology in half-life extension of small-molecule drugs after intravitreal injection
Finance
Heptares Therapeutics enters agreement with Daichi Sankyo
The collaboration aims to discover and develop novel, small-molecules for the treatment of pain
Pharmaceutical
Amgen and Daiichi Sankyo to commercialise biosimilars in Japan
The exclusive agreement includes nine biosimilars in late-stage development
Drug Delivery
Nitto Denko enters drug delivery partnership with Daiichi Sankyo
To accelerate the commercialisation of Nitto’s PassPort transdermal drug delivery technology
Research & Development
Daiichi Sankyo appoints Antoine Yver as Global Head, Oncology Research and Development
He will lead all global R&D across the oncology therapeutic area
Subscribe now